DOCSLIB.ORG

Abstract Characterization of the Mlr19 Transgenic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Characterization of the Mlr19 Transgenic ABSTRACT CHARACTERIZATION OF THE MLR19 TRANSGENIC MOUSE LINE AND THE ROLE OF MYOCARDIN IN THE BLADDER By Kevin David Wright Obstructive uropathy is the leading cause of the end-stage renal failure in children, yet there remain few genetic animal models to study this disorder. The MLR19 megabladder mice are a transgene-induced insertional mutant mouse line that fails to develop the smooth muscle surrounding the urinary bladder, creating an obstructive uropathy. The aim of this project is to further characterize the MLR19 mutants to determine what gene is being affected to cause the phenotype. Complementation studies suggest that myocardin is the relevant gene in the MLR19 megabladder phenotype, even though the transgene insertion is 335kb upstream from myocardin. Morphometric analysis of MLR19 heterozygotes and myocardin heterozygotes suggests that even mild reductions in myocardin have a significant effect on thickness of the bladder smooth muscle. Together, these data support the conclusion that myocardin is a critical gene involved in the development of the urinary bladder smooth muscle. CHARACTERIZATION OF THE MLR19 TRANSGENIC MOUSE LINE AND THE ROLE OF MYOCARDIN IN THE BLADDER A Thesis Submitted to the Faculty of Miami University In partial fulfillment of The requirements for the degree of Master of Science Department of Zoology by Kevin David Wright Miami University Oxford, Ohio 2009 Advisor ________________________________ Dr. Michael L. Robinson Reader _________________________________ Dr. Joyce Fernandes Reader _________________________________ Dr. Paul Schaeffer Reader _________________________________ Dr. Yoshinori Tomoyasu TABLE OF CONTENTS TITLE PAGE i TABLE OF CONTENTS ii LIST OF FIGURES AND TABLES iii ACKNOWLEDGEMENTS iiii CHAPTERS 1. Introduction 1 2. Targeted knock-out Construct for 24kb region on chromosome 11 14 2.1. Introduction 14 2.2. Materials and Methods 15 2.3. Results and Discussion 18 3. Complementation study to determine myocardin’s role in MLR19 phenotype 32 3.1. Introduction 32 3.2. Materials and Methods 32 3.3. Results and Discussion 34 4. Morphometric analysis of urinary bladder smooth muscle 43 4.1. Introduction 43 4.2. Materials and Methods 43 4.3. Results and Discussion 44 6. Conclusions 50 APPENDIX 53 REFERENCES 55 ii LIST OF TABLES Tables page 2.1 Primers to amplify the 5’ and 3’ homology arm for knockout construct 22 3.1 Primers used to genotype the MLR19 and Myocardin mutants 37 3.2 Ureter lumen area of MLR19-/myocd- and wild type animals 38 4.1 Mean thickness of the bladder smooth muscle in WT, MLR19+/-, and Myocd+/- 47 iii LIST OF FIGURES Figures page 1.1 Urinary bladder development 11 1.2 WT and MLR19-/- bladders and map of MLR19 mutation 12 1.3 Map of myocardin cardiac and smooth muscle isoforms 13 2.1 Diagram showing location of the homology arm primers 23 2.2 Maps of plasmids PL451 and PL253 24 2.3 Restriction digests showing successful ligation of 5’ homology arm into pl451 25 2.4 Restriction digests showing successful ligation of 3’ homology arm into pl451+5’ arm 26 2.5 Restriction digests showing successful ligation of TK gene into pl451+homology arms 27 2.6 Sequences of ligation junctions in the completed knockout construct 29 2.7 Diagram summarizing Southern blot strategy for screening ES cells 31 3.1 Diagram of MLR19-/myocd- breeding plan with chromosome 11 39 3.2 PCR and gross histology of MLR19-/myocd- compound heterozygotes 40 3.3 Hemotoxylin and Eosin staining of MLR19-/Myocd- compound heterozygotes 41 3.4 Immuhistochemistry of smooth muscle actin in newborn urinary bladders 42 4.1 Comparison of wild type, MLR19+/-, Myocd+/- bladder smooth muscle thickness 48 4.2 Comparison in lumen area between wild type, MLR19+/-, and Myocd+/- animals 49 Appendix A. Myocardin western blot analysis 56 iv ACKNOWLEDGEMENTS I thank Dr. Michael Robinson for his guidance, patience and support throughout my work in his lab. I thank Dr. Joyce Fernandes, Dr. Paul Schaeffer, and Dr. Yoshinori Tomoyasu for sitting on my committee as well as for their valuable input on the project. I thank Brad Wagner for all his help in the lab, without him our lab would not function as well as it does. I would also like to thank other members of the Robinson lab for their companionship and insight into the project. Thanks for making the lab a great place to work. I thank Kristen Lucia and Dr. Robert Schaefer for their help running the statistics, and Dr. John Hawes for his help and insight with the protein analysis aspect of the project. I would like to thank everyone in the Department of Zoology, for creating a great work environment and providing assistance when needed. I would especially like to thank my parents, family and friends, without them I would not be the person I am today. Your constant support and love are truly appreciated. v CHAPTER 1. Introduction Obstructive uropathy Obstructive uropathy (OU) is any urinary tract abnormality caused by an obstruction at any level of the urinary tract (Roth et al. 2002, Becker and Baum 2006). There are many different disorders that cause obstructions, including: kidney stones, ureterocele, urethral valve blockages, and prune belly syndrome. If left untreated, these disorders often result in mild to severe kidney damage from hydronephrosis. Hydronephrosis is a condition caused by the buildup of hydrostatic pressure proximal to the obstruction. The urinary back pressure causes dilation of the ureters and ultimately dilation of the kidneys (hydronephrosis) (Peters 1995, Roth et al. 2002). In many of the severe conditions, the urinary tract is obstructed for long periods of time causing irreversible damage to the kidneys leading to end-stage renal disease (ESRD) a condition where the kidneys are unable to maintain organismal homeostasis. This leads many patients with ESRD to a lifelong dependency on dialysis or the need for renal transplant. The most severe cases can even lead to death. In children needing renal transplants, obstructive uropathies are the leading cause accounting for approximately 22% of children with renal insufficiency and leading to 1,538 transplants from 1987 to 2008 in North America alone (Benfield et al. 2003, Warady and Chadha 2006, Morris and Kilby 2008). For children with urinary tract obstructions, without intervention, surgical or otherwise, the condition can be lethal shortly after birth. Congenital uropathies are often due to structural deformities that lead to blockage during the development of the urinary system in the fetus. While the blockage can be surgically removed and normal urinary system function restored many children still develop ESRD. Because of this, there remains a need to understand what is happening to the renal and urinary systems at the cellular and biochemical level during and post obstruction to better understand kidney function and the potential long term implications of the blockage. Even at the state-of-the-art strategic planning workshop hosted by the American Society of Pediatric Nephrology and NIH, this need was listed as the first major aim for future research goals (Chevalier and Peters 2003). Animal Models to Study the Cause and Pathology of Obstructive Uropathies To date there are few spontaneous animal models where obstructive uropathies, that occur during renal development, can be studied (Peters 1997, Peters 2001, Bascands and 1 Shanstra 2005). One such model is the Congenital progressive hydronephrosis (cph) mouse strain that develops a progressive hydronephrosis (Horton et al. 1988) from overproduction of urine. However, the cph mice do not have an obstruction prior to the urine accumulation; it is the inability to void the large amounts of urine that produces the obstruction (McDill et al. 2006). Since, many of the cases of OU in children are not due to overproduction of urine, but by obstruction, the cph mice are an insufficient model to study the progression to ESRD due to obstruction. As an alternative to spontaneous (genetic) models of obstructive uropathy, researchers have created surgical models in which different portions of the urinary tract are artificially ligated to form an obstruction. This method has been performed in a wide array of animal models including sheep, pig, canine, and opossum (reviewed in Peters 2001). This method of creating urinary obstructions has several advantages, such as having the option to choose which level of the urinary tract to obstruct and the predictability in which the specimens develop pathological symptoms. Yet, with these advantages, there are also drawbacks - the surgeries are extremely invasive and some models, such as rabbits, are sensitive to the anesthesia and have a high mortality rate with surgery (Peters 2001). Also, larger animals that are more amendable to surgical obstruction are often extremely costly to keep and maintain. Sheep have been the favored animal model for induced obstructive uropathies for many years, as the size of the sheep, both adult and fetal, are convenient for surgery. This model has provided great insight into the effects of obstruction on the kidneys (reviewed in Peters 1997). However, one of the drawbacks of this model is that females only have one or two offspring each pregnancy, after a relatively lengthy gestation period, making sheep an inconvenient model for large scale studies using multiple fetal specimens. Disadvantages like this, and the time cost of performing the surgeries have led to a desire for genetic models of functional obstructive uropathies in smaller animal models such as mice. One of the other main advantages of using mice as a model system includes the wealth of genetic information and the ease of manipulating the mouse genome to create mutants that will help give a better understanding the genes/molecules required for normal urinary system function. Currently, there are very few genetic mouse models where the animals develop obstructive uropathies without having severe developmental defects that affect multiple organ systems.
Load more

Recommended publications
  • MKL1 (C) Antibody, Rabbit Polyclonal
    Order: (888)-282-5810 (Phone) (818)-707-0392 (Fax) [email protected] Web: www.Abiocode.com MKL1 (C) Antibody, Rabbit Polyclonal Cat#: R2403-2 Lot#: Refer to vial Quantity: 100 ul Application: WB Predicted I Observed M.W.: 99 I 140 kDa Uniprot ID: Q969V6 Background: MKL/myocardin-like protein 1 (MKL1) is a transcriptional coactivator of serum response factor (SRF) with the potential to modulate SRF target genes. MKL1 suppresses TNF-induced cell death by inhibiting activation of caspases; its transcriptional activity is indispensable for the antiapoptotic function. MKL1 may up-regulate antiapoptotic molecules, which in turn inhibit caspase activation. Other Names: MKL/myocardin-like protein 1, Megakaryoblastic leukemia 1 protein, Megakaryocytic acute leukemia protein, Myocardin-related transcription factor A, MRTF-A, KIAA1438, MAL Source and Purity: Rabbit polyclonal antibodies were produced by immunizing animals with a GST-fusion protein containing the C-terminal region of human MKL1. Antibodies were purified by affinity purification using immunogen. Storage Buffer and Condition: Supplied in 1 x PBS (pH 7.4), 100 ug/ml BSA, 40% Glycerol, 0.01% NaN3. Store at -20 °C. Stable for 6 months from date of receipt. Species Specificity: Human Tested Applications: WB: 1:1,000-1:3,000 (detect endogenous protein*) *: The apparent protein size on WB may be different from the calculated M.W. due to modifications. For research use only. Not for therapeutic or diagnostic purposes. Abiocode, Inc., 29397 Agoura Rd., Ste 106, Agoura Hills, CA 91301 Order: (888)-282-5810 (Phone) (818)-707-0392 (Fax) [email protected] Web: www.Abiocode.com Product Data: kDa A B 250 150 100 75 50 37 Fig 1.
    [Show full text]
  • Wide-Scale Analysis of Human Functional Transcription Factor
    Wide-Scale Analysis of Human Functional Transcription Factor Binding Reveals a Strong Bias towards the Transcription Start Site Yuval Tabach1,2, Ran Brosh2, Yossi Buganim2, Anat Reiner1, Or Zuk1, Assif Yitzhaky1, Mark Koudritsky1, Varda Rotter2 and Eytan Domany1,* 1Departments of Physics of Complex Systems and 2Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel *Corresponding author. Email: [email protected] Tel: +972-8-9343964 Fax: +972-8- 9344109 Running title: Binding Sites Location Bias Keywords: Transcription factor binding sites, location bias, cell cycle, NF-kB, promoter, Gene Ontology, TATA, myocardin 1 Summary Background: Elucidating basic principles that underlie regulation of gene expression by transcription factors (TFs) is a central challenge of the post-genomic era. Transcription factors regulate expression by binding to specific DNA sequences; such a binding event is functional when it affects gene expression. Functionality of a binding site is reflected in conservation of the binding sequence during evolution and in over represented binding in gene groups with coherent biological functions. Functionality is governed by several parameters such as the TF- DNA binding strength, distance of the binding site from the transcription start site (TSS), DNA packing, and more. Understanding how these parameters control functionality of different TFs in different biological contexts is an essential step towards identifying functional TF binding sites, a must for understanding regulation of transcription. Methodology/Principal Findings: We introduce a novel method to screen the promoters of a set of genes with shared biological function, against a precompiled library of motifs, and find those motifs which are statistically over-represented in the gene set.
    [Show full text]
  • Co-Occupancy by Multiple Cardiac Transcription Factors Identifies
    Co-occupancy by multiple cardiac transcription factors identifies transcriptional enhancers active in heart Aibin Hea,b,1, Sek Won Konga,b,c,1, Qing Maa,b, and William T. Pua,b,2 aDepartment of Cardiology and cChildren’s Hospital Informatics Program, Children’s Hospital Boston, Boston, MA 02115; and bHarvard Stem Cell Institute, Harvard University, Cambridge, MA 02138 Edited by Eric N. Olson, University of Texas Southwestern, Dallas, TX, and approved February 23, 2011 (received for review November 12, 2010) Identification of genomic regions that control tissue-specific gene study of a handful of model genes (e.g., refs. 7–10), it has not been expression is currently problematic. ChIP and high-throughput se- evaluated using unbiased, genome-wide approaches. quencing (ChIP-seq) of enhancer-associated proteins such as p300 In this study, we used a modified ChIP-seq approach to define identifies some but not all enhancers active in a tissue. Here we genome wide the binding sites of these cardiac TFs (1). We show that co-occupancy of a chromatin region by multiple tran- provide unbiased support for collaborative TF interactions in scription factors (TFs) identifies a distinct set of enhancers. GATA- driving cardiac gene expression and use this principle to show that chromatin co-occupancy by multiple TFs identifies enhancers binding protein 4 (GATA4), NK2 transcription factor-related, lo- with cardiac activity in vivo. The majority of these multiple TF- cus 5 (NKX2-5), T-box 5 (TBX5), serum response factor (SRF), and “ binding loci (MTL) enhancers were distinct from p300-bound myocyte-enhancer factor 2A (MEF2A), here referred to as cardiac enhancers in location and functional properties.
    [Show full text]
  • Myocardin (MYOCD) (NM 001146312) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC229055L3 Myocardin (MYOCD) (NM_001146312) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: Myocardin (MYOCD) (NM_001146312) Human Tagged ORF Clone Tag: Myc-DDK Symbol: MYOCD Synonyms: MGBL; MYCD Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC229055). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_001146312 ORF Size: 2958 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 Myocardin (MYOCD) (NM_001146312) Human Tagged ORF Clone – RC229055L3 OTI Disclaimer: Due to the inherent nature of this plasmid, standard methods to replicate additional amounts of DNA in E. coli are highly likely to result in mutations and/or rearrangements. Therefore, OriGene does not guarantee the capability to replicate this plasmid DNA. Additional amounts of DNA can be purchased from OriGene with batch-specific, full-sequence verification at a reduced cost. Please contact our customer care team at [email protected] or by calling 301.340.3188 option 3 for pricing and delivery. The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g.
    [Show full text]
  • Gene Expression During Normal and FSHD Myogenesis Tsumagari Et Al
    Gene expression during normal and FSHD myogenesis Tsumagari et al. Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 (27 September 2011) Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 RESEARCHARTICLE Open Access Gene expression during normal and FSHD myogenesis Koji Tsumagari1, Shao-Chi Chang1, Michelle Lacey2,3, Carl Baribault2,3, Sridar V Chittur4, Janet Sowden5, Rabi Tawil5, Gregory E Crawford6 and Melanie Ehrlich1,3* Abstract Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis- specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction.
    [Show full text]
  • Myocardin Is Sufficient and Necessary for Cardiac Gene Expression in Xenopus Eric M
    Research article 987 Myocardin is sufficient and necessary for cardiac gene expression in Xenopus Eric M. Small1,*,†, Andrew S. Warkman1,*, Da-Zhi Wang2, Lillian B. Sutherland3, Eric N. Olson3 and Paul A. Krieg1,‡ 1Department of Cell Biology and Anatomy, University of Arizona Health Sciences Center, 1501 N. Campbell Avenue, PO Box 245044, Tucson, AZ, 85724, USA 2Carolina Cardiovascular Biology Center, Department of Cell and Developmental Biology, University of North Carolina, Chapel Hill, NC 27599-7126, USA 3Department of Molecular Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9148, USA *These authors contributed equally to this work †Present address: Cardiovascular Research, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada ‡Author for correspondence (e-mail: [email protected]) Accepted 14 December 2004 Development 132, 987-997 Published by The Company of Biologists 2005 doi:10.1242/dev.01684 Summary Myocardin is a cardiac- and smooth muscle-specific co- expression. Inhibition of myocardin activity in Xenopus factor for the ubiquitous transcription factor serum embryos using morpholino knockdown methods results in response factor (SRF). Using gain-of-function approaches inhibition of cardiac development and the absence of in the Xenopus embryo, we show that myocardin is expression of cardiac differentiation markers and severe sufficient to activate transcription of a wide range of disruption of cardiac morphological processes. We cardiac and
    [Show full text]
  • Regulation of Mitochondrial Function by Myocardin During Cardiac Development and Disease
    Regulation of mitochondrial function by Myocardin during cardiac development and disease By Wajihah Mughal A Thesis submitted to the Faculty of Graduate Studies University of Manitoba In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Department of Human Anatomy and Cell Science University of Manitoba Winnipeg Copyright © by Wajihah Mughal, 2019 Abstract Metabolic specific myogenic precursors in the splanchnic, somatic mesoderm, and the neural crest give rise to specialized cell types such as cardiac, skeletal, and smooth muscle cells. This initiation of muscle cell lineage is coordinated by a reinforcing networking of transcription factors that regulate gene expression during cell proliferation and differentiation. Myocardin is a transcriptional coactivator that binds to transcription factors to regulate gene expression specific to both cardiac and smooth muscle cells. It is previously shown that Myocardin interacts with transcription factors of the MADS-Box family proteins such as myocyte enhancer factor-2 (MEF2) and serum response factor (SRF), that are known regulators of cellular differentiation and metabolism. Conversely, the role of Myocardin as well as its regulation of MADS-Box transcription factors and mitochondrial function during development and disease is not well understood. Therefore, we chose to investigate a Myocardin-regulated genetic pathway that regulates mitochondrial function in cardiac muscle that becomes dysregulated during disease. My thesis summarizes our evaluation of the hypothesis in two studies. In the first study we characterize a mechanistic pathway involving MEF2 and SRF, that regulates mitochondrial function in all three muscle lineages. This initial study demonstrates a genetic pathway in which Nix is a direct target of miR-133a, its role in regulating insulin sensitivity and metabolic dysfunction in myocytes.
    [Show full text]
  • Loss-Of-Function Variants in Myocardin Cause Congenital Megabladder in Humans and Mice
    Loss-of-function variants in myocardin cause congenital megabladder in humans and mice Arjan C. Houweling, … , Adrian S. Woolf, Esther E. Creemers J Clin Invest. 2019. https://doi.org/10.1172/JCI128545. Concise Communication In-Press Preview Muscle biology Myocardin (MYOCD) is the founding member of a class of transcriptional co-activators that bind serum response factor to activate gene expression programs critical in smooth muscle (SM) and cardiac muscle development. Insights into the molecular functions of MYOCD have been obtained from cell culture studies and, to date, knowledge about in vivo roles of MYOCD comes exclusively from experimental animals. Here, we defined an often lethal congenital human disease associated with inheritance of pathogenic MYOCD variants. This disease manifested as a massively dilated urinary bladder, or megabladder, with disrupted SM in its wall. We provided evidence that monoallelic loss-of-function variants in MYOCD caused congenital megabladder in males only, whereas biallelic variants were associated with disease in both sexes, with a phenotype additionally involving the cardiovascular system. These results were supported by co- segregation of MYOCD variants with the phenotype in four unrelated families, by in vitro transactivation studies where pathogenic variants resulted in abrogated SM gene expression, and finding megabladder in two distinct mouse models with reduced Myocd activity. In conclusion, we have demonstrated that variants in MYOCD result in human disease, and the collective findings highlight a vital role for MYOCD in mammalian organogenesis. Find the latest version: https://jci.me/128545/pdf Loss-of-function variants in myocardin cause congenital megabladder in humans and mice Arjan C.
    [Show full text]
  • The Myocardin Family of Transcriptional Coactivators: Versatile Regulators of Cell Growth, Migration, and Myogenesis
    Downloaded from genesdev.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis G.C. Teg Pipes, Esther E. Creemers, and Eric N. Olson1 Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA The association of transcriptional coactivators with se- gene regulation and expands the regulatory potential of quence-specific DNA-binding proteins provides versatil- individual cis-regulatory elements. ity and specificity to gene regulation and expands the The regulation of serum response factor (SRF) and its regulatory potential of individual cis-regulatory DNA se- target genes provides a classic example of the diversity of quences. Members of the myocardin family of coactiva- genes controlled by a single DNA-binding protein and tors activate genes involved in cell proliferation, migra- the importance of cofactor interactions in the control of tion, and myogenesis by associating with serum re- gene expression (Shore and Sharrocks 1995). Among the sponse factor (SRF). The partnership of myocardin family many target genes of SRF are genes involved in cell pro- members and SRF also controls genes encoding compo- liferation and muscle differentiation, which represent nents of the actin cytoskeleton and confers responsive- opposing programs of gene expression: Muscle genes are ness to extracellular growth signals and intracellular repressed by growth factor signals and generally do not changes in the cytoskeleton, thereby creating a tran- become activated until myoblasts exit the cell cycle. The scriptional–cytoskeletal regulatory circuit. These func- ability of SRF to regulate different sets of downstream tions are reflected in defects in smooth muscle differen- effector genes depends on its association with positive tiation and function in mice with mutations in myocar- and negative cofactors (Treisman 1994; Shore and Shar- din family members.
    [Show full text]
  • Signaling and Transcriptional Networks in Heart Development and Regeneration
    Downloaded from http://cshperspectives.cshlp.org/ on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Signaling and Transcriptional Networks in Heart Development and Regeneration Benoit G. Bruneau Gladstone Institute of Cardiovascular Disease, San Francisco, California 94158, and Department of Pediatrics and Cardiovascular Research Institute, University of California, San Francisco, California 94158 Correspondence: [email protected] SUMMARY The mammalian heart is the first functional organ, the first indicator of life. Its normal formation and function are essential for fetal life. Defects in heart formation lead to congenital heart defects, underscoring the finesse with which the heart is assembled. Understanding the reg- ulatory networks controlling heart development have led to significant insights into its lineage origins and morphogenesis and illuminated important aspects of mammalian embryology, while providing insights into human congenital heart disease. The mammalian heart has very little regenerative potential, and thus, any damage to the heart is life threatening and perma- nent. Knowledge of the developing heart is important for effective strategies of cardiac regen- eration, providing new hope for future treatments for heart disease. Although we still have an incomplete picture of the mechanisms controlling development of the mammalian heart, our current knowledge has important implications for embryology and better understanding of human heart disease. Outline 1 Introduction 4 Heart repair and
    [Show full text]
  • Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell L
    cancers Article Inhibition of the Myocardin-Related Transcription Factor Pathway Increases Efficacy of Trametinib in NRAS-Mutant Melanoma Cell Lines Kathryn M. Appleton 1, Charuta C. Palsuledesai 1, Sean A. Misek 2, Maja Blake 1, Joseph Zagorski 1, Kathleen A. Gallo 2, Thomas S. Dexheimer 1 and Richard R. Neubig 1,3,* 1 Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA; [email protected] (K.M.A.); [email protected] (C.C.P.); [email protected] (M.B.); [email protected] (J.Z.); [email protected] (T.S.D.) 2 Department of Physiology, Michigan State University, East Lansing, MI 48824, USA; [email protected] (S.A.M.); [email protected] (K.A.G.) 3 Department of Medicine, Division of Dermatology, Michigan State University, East Lansing, MI 48824, USA * Correspondence: [email protected]; Tel.: +1-517-353-7145 Simple Summary: Malignant melanoma is the most aggressive skin cancer, and treatment is often ineffective due to the development of resistance to targeted therapeutic agents. The most prevalent form of melanoma with a mutated BRAF gene has an effective treatment, but the second most common mutation in melanoma (NRAS) leads to tumors that lack targeted therapies. In this study, we show that NRAS mutant human melanoma cells that are most resistant to inhibition of the oncogenic pathway have a second activated pathway (Rho). Inhibiting that pathway at one of several Citation: Appleton, K.M.; points can produce more effective cell killing than inhibition of the NRAS pathway alone. This raises Palsuledesai, C.C.; Misek, S.A.; Blake, the possibility that such a combination treatment could prove effective in those melanomas that fail M.; Zagorski, J.; Gallo, K.A.; to respond to existing targeted therapies such as vemurafenib and trametinib.
    [Show full text]
  • Genome-Wide RNA-Sequencing Analysis Identifies a Distinct
    www.nature.com/scientificreports OPEN Genome-wide RNA-Sequencing analysis identifies a distinct fibrosis gene signature in the conjunctiva Received: 16 March 2017 Accepted: 27 June 2017 after glaucoma surgery Published: xx xx xxxx Cynthia Yu-Wai-Man1,2, Nicholas Owen2, Jonathan Lees3, Aristides D. Tagalakis4, Stephen L. Hart 4, Andrew R. Webster1,2, Christine A. Orengo3 & Peng T. Khaw1,2 Fibrosis-related events play a part in most blinding diseases worldwide. However, little is known about the mechanisms driving this complex multifactorial disease. Here we have carried out the first genome-wide RNA-Sequencing study in human conjunctival fibrosis. We isolated 10 primary fibrotic and 7 non-fibrotic conjunctival fibroblast cell lines from patients with and without previous glaucoma surgery, respectively. The patients were matched for ethnicity and age. We identified 246 genes that were differentially expressed by over two-fold andp < 0.05, of which 46 genes were upregulated and 200 genes were downregulated in the fibrotic cell lines compared to the non-fibrotic cell lines. We also carried out detailed gene ontology, KEGG, disease association, pathway commons, WikiPathways and protein network analyses, and identified distinct pathways linked to smooth muscle contraction, inflammatory cytokines, immune mediators, extracellular matrix proteins and oncogene expression. We further validated 11 genes that were highly upregulated or downregulated using real-time quantitative PCR and found a strong correlation between the RNA-Seq and qPCR results. Our study demonstrates that there is a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery and provides new insights into the mechanistic pathways driving the complex fibrotic process in the eye and other tissues.
    [Show full text]